LAMPROS MITRAKAS

Dr. LAMPROS MITRAKAS

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
KEKonstantinos Evmorfopoulos
Konstantinos Evmorfopoulos
LMLAMPROS MITRAKAS
LAMPROS MITRAKAS
AKAthanasios Karathanasis
Athanasios Karathanasis
IZIoannis Zachos
Ioannis Zachos
VTVassilios Tzortzis
Vassilios Tzortzis
PVPanagiotis Vlachostergios
Panagiotis Vlachostergios
Upper tract urothelial carcinoma (UTUC) is a rare malignancy, occurring in 5–10% of patients diagnosed with UC, and involves the renal pelvis, calyces, or ureters. UTUC can be sporadic or hereditary as a clinical manifestation of Lynch syndrome. Therapeutic management of these patients is challenging. Following risk stratification of localized disease, patients with low-grade UTUC may undergo kidney-sparing surgery or radical nephroureterectomy (RNU) and/or chemoablation with mitomycin-c instillation to reduce recurrence. In high-grade disease, RNU followed by adjuvant chemotherapy remains the standard of care. For decades, platinum-based chemotherapy has been the cornerstone of treatment for locally advanced and metastatic disease. The aim of the present review is to summarize recent advances in UTUC’s therapeutic management through the lens of its genomic and immune landscape. Accumulating knowledge on the genetic and immune aspects of UTUC tumors has increased our understanding of their underlying biology, supporting a luminal papillary, T-cell depleted contexture and enrichment in fibroblast growth factor receptor (FGFR) expression. These advances have fueled successful clinical testing of several precision-based therapeutic approaches, including immune checkpoint inhibitors (ICIs), the antibody–drug conjugates (ADCs) enfortumab vedotin and sacituzumab govitecan, and agents targeting the FGFR axis such as erdafitinib and other kinase inhibitors, allowing their entry into the therapeutic armamentarium and improving the prognosis of these patients. Not all patients respond to these precision-based targeted therapies; thus, validating and expanding the toolkit of potential biomarkers of response or resistance, including molecular subtypes, FGFR pathway gene alterations, DNA repair gene defects, tumor mutational burden (TMB), circulating tumor DNA (ctDNA), nectin-4, TROP2, and programmed death ligand-1 (PD-L1), are key to maximizing the benefit to these particular subgroups of patients.

14 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
PVPanagiotis Vlachostergios
Panagiotis Vlachostergios
ITIoannis Tamposis
Ioannis Tamposis
MAMaria Anagnostou
Maria Anagnostou
MPMaria Papathanassiou
Maria Papathanassiou
LMLAMPROS MITRAKAS
LAMPROS MITRAKAS
VTVassilios Tzortzis
Vassilios Tzortzis
Background: Hypoxia is recognized as a key feature of cancer growth and is involved in various cellular processes, including proliferation, angiogenesis, and immune surveillance. Besides hypoxia-inducible factor 1-alpha (HIF-1α), which is the main mediator of hypoxia effects and can also be activated under normoxic conditions, little is known about its counterpart, HIF-2. This study focused on investigating the clinical and molecular landscape of HIF-2-altered urothelial carcinoma (UC). Methods: Publicly available next-generation sequencing (NGS) data from muscle-invasive UC cell lines and patient tumor samples from the MSK/TCGA 2020 cohort (n = 476) were interrogated for the level of expression (mRNA, protein) and presence of mutations, copy number variations, structural variants in the EPAS1 gene encoding HIF-2, and findings among various clinical (stage, grade, progression-free and overall survival) and molecular (tumor mutational burden, enriched gene expression) parameters were compared between altered and unaltered tumors. Results: 19% (7/37) of UC cell lines and 7% (27/380) of patients with muscle-invasive UC display high EPAS1 mRNA and protein expression or/and EPAS1 alterations. EPAS1-altered tumors are associated with higher stage, grade, and lymph node metastasis as well as with shorter PFS (14 vs. 51 months, q = 0.01) and OS (15 vs. 55 months, q = 0.01). EPAS1 mRNA expression is directly correlated with that of its target-genes, including VEGF, FLT1, KDR, DLL4, CDH5, ANGPT1 (q < 0.001). While there is a slightly higher tumor mutational burden in EPAS1-altered tumors (9.9 vs. 4.9 mut/Mb), they are enriched in and associated with genes promoting immune evasion, including ARID5B, SPINT1, AAK1, CLIC3, SORT1, SASH1, and FGFR3, respectively (q < 0.001). Conclusions: HIF-2-altered UC has an aggressive clinical and a distinct genomic and immunogenomic profile enriched in angiogenesis- and immune evasion-promoting genes.

28 January 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
LMLAMPROS MITRAKAS
LAMPROS MITRAKAS
SGStavros Gravas
Stavros Gravas
FKFoteini Karasavvidou
Foteini Karasavvidou
GDGeorgios Dimakopoulos
Georgios Dimakopoulos
GMGeorgios Moutzouris
Georgios Moutzouris
MMMelekos Michael
Melekos Michael

12 September 2022 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
PDF file
FKFoteini Karasavvidou
Foteini Karasavvidou
LMLAMPROS MITRAKAS
LAMPROS MITRAKAS
STStyliani Tzika
Styliani Tzika
IZIoannis Zachos
Ioannis Zachos
AAATHANASIOS ASTERIOS ANAGNOSTOU
ATHANASIOS ASTERIOS ANAGNOSTOU
VTVassilios Tzortzis
Vassilios Tzortzis
The mixed epithelial and stromal tumor family of kidney contain neoplasms with biphasic epithelial and stromal component. According to the 2016 World Health Organization Classification, they encompasses a spectrum of tumors ranging from predominantly cystic tumors (adult cystic nephroma) to tumors that are variably solid (Mixed epithelial and stromal tumor-MESTs). We present the case of a 20-year-old woman with an adult cystic nephroma which was verified by immunohistochemical examination.

15 November 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
MSMARIA SAMARA
MARIA SAMARA
MPMaria Papathanassiou
Maria Papathanassiou
IFIoanna Farmakioti
Ioanna Farmakioti
MAMaria Anagnostou
Maria Anagnostou
MSMaria Satra
Maria Satra
PVPanagiotis Vlachostergios
Panagiotis Vlachostergios
The renin-angiotensin system (RAS), besides being a major regulator of blood pressure, is also involved in tumor angiogenesis. Emerging evidence suggests a correlation between the use of pharmacologic RAS inhibitors and a delay in urothelial bladder cancer (BC) progression. However, it is unknown whether RAS gene variants may predispose to the development of BC. This study examined the association of RAS single nucleotide polymorphisms (SNPs) including AT1R rs5186, AT2R rs11091046, REN rs12750834, ANG rs4762, and ANG rs699 with the risk of developing non-invasive BC. Peripheral blood samples from 73 patients with T1 urothelial BC (66 men, seven women) and an equal number of healthy subjects (control group) were collected. The TT genotype of the REN rs12750834 SNP (OR: 2.8 [1.3–6.05], p = 0.008) and to a lesser extent the presence of the T allele (OR: 2.3 [1.2–4.48], p = 0.01) conferred a higher risk of BC. The highest risk for BC within SNP carriers of the RAS system was associated with the presence of the CC genotype (OR: 17.6 [7.5–41.35], p < 0.001) and C allele (OR: 17.7 [8.8–35.9], p < 0.001) of the ANG rs699 SNP. The presence of the AT2R rs11091046 SNP, particularly the AA genotype, was associated with a protective effect against developing BC (OR: 0.268 [0.126–057], p < 0.001). In conclusion, these results support the clinical utility of RAS gene SNPs AT2R rs11091046, REN rs12750834, and ANG rs699 in the genetic cancer risk assessment of patients and families with BC.

11 April 2022 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
PDF file
FKFoteini Karasavvidou
Foteini Karasavvidou
LMLAMPROS MITRAKAS
LAMPROS MITRAKAS
MSMaria Strataki
Maria Strataki
DADimitrios Anastasiou
Dimitrios Anastasiou
GKGeorgios Koukoulis
Georgios Koukoulis
VTVassilios Tzortzis
Vassilios Tzortzis
Urothelial carcinoma of the urinary bladder is a common clinical entity. Recently, researchers focused on the emerging clinical significance of histologic variants, because they may need special therapy and their prognosis differs. Hereby, we describe a case of a giant cell osteoclast-like urothelial carcinoma of the urinary bladder.